Interleukin-10-based therapy for inflammatory bowel disease

Bibliography

• VAN DEVENTER SJ: Taming the mucosal immune response in Crohn's disease. Best Freer Res. Clin. Gastroenterol (2002) 16:1035–1043.
   PubMed Web of Science ®Google Scholar
• KUHN R, LOHLERJ, RENNICK D, RAJEWSKY K, MULLER W: Interleukin-10-deficient mice develop chronic enterocolitis. Cell (1993) 75:263–274.
   PubMed Web of Science ®Google Scholar
• SELLON RK, TONKONOGY S, SCHULTZ M et al: Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect. Inman. (1998) 66:5224–5231.
   PubMed Web of Science ®Google Scholar
• SCHREIBER S, FEDORAK RN, NIELSEN OH et al.: Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 119:1461–1472.
   Google Scholar
• •First study which used IL-10 as a treatment for CD.
   Google Scholar
• VAN DEVENTER SJ, ELSON CO, FEDORAK RN: Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology (1997) 113:383–389.
   PubMed Web of Science ®Google Scholar
• NAKASE H, OKAZAKI K, TABATA Y et al: New cytokine delivery system using gelatin microspheres containing interleukin-10 for experimental inflammatory bowel disease.' Phannacol. Exp. Ther. (2002) 301:59–65.
   PubMed Web of Science ®Google Scholar
• OKAZAKI K, NAKASE H, WATANABE N et al.: Intestinal drug delivery systems with biodegradable microspheres targeting mucosal immune-regulating cells for chronic inflammatory colitis.' Gastroenterol. (2002) 37\(Suppl. 14):44–52.
   Google Scholar
• STEIDLER L, HANS W, SCHOTTE L et al.: Treatment of murine colitis by Lactococcus /actissecreting interleukin-10. Science (2000) 289:1352–1355.
   PubMed Web of Science ®Google Scholar
• ••Describes the potential use of recombinantbacteria as a treatment for CD.
   Google Scholar
• VIEIRA P, DE WAAL-MALEFYT R, DANG MN et al.: Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc. Nati Acad. Sci. USA (1991) 88:1172–1176.
   PubMed Web of Science ®Google Scholar
• JONULEIT H, SCHMITT E, STEINBRINK K, ENK AH: Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Innnunol. (2001) 22:394–400.
   PubMed Web of Science ®Google Scholar
• LINDSAY J, VAN MONTFRANS C, BRENNAN F et al.: IL-10 gene therapy prevents TNBS-induced colitis. Gene Ther. (2002) 9:1715–1721.
   PubMed Web of Science ®Google Scholar
• VAN MONTFRANS C, RODRIGUEZ PENA MS, PRONK let al.: Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model. Gastroenterology (2002) 123:1865–1876.
   Google Scholar
• ••Proof of principle for the use of genetherapy of T cells in CD.
   Google Scholar
• BARBARA G, XING Z, HOGABOAM CM, GAULDIE J, COLLINS SM: Interleukin 10 gene transfer prevents experimental colitis in rats. Gut (2000) 46:344–349.
   PubMed Web of Science ®Google Scholar
• SALEK-ARDAKANI S, ARRAND JR, MACKETT M: Epstein-Barr virus encoded interleukin-10 inhibits HLA-class I, ICAM-1, and B7 expression on human monocytes: implications for immune evasion by EBV Virology (2002) 304:342–351.
   Google Scholar
• ZDANOV A, SCHALK-HIHI C, GUSTCHINA A et al.: Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon gamma. Structure (1995) 3:591–601.
   PubMed Web of Science ®Google Scholar
• HO AS, LIU Y, KHAN TA et al.: A receptor for interleukin 10 is related to interferon receptors. Proc. Nati Acad. Sci. USA (1993) 90:11267–11271.
   PubMed Web of Science ®Google Scholar
• BOURREILLE A, SE GAIN JP, RAIN GEARD DE LA BLETIERE D et al.: Lack of interleukin 10 regulation of antigen presentation-associated molecules expressed on colonic epithelial cells. Eur. Clin. Invest. (1999) 29:48–55.
   Google Scholar
• MOORE KW, DE WAAL MALEFYT R, COFFMAN RL, O'GARRA A: Interleukin-10 and the interleukin-10 receptor. Ann. Rev Innnunol. (2001) 19:683–765.
   PubMed Web of Science ®Google Scholar
• •Extensive review on IL-10.
   Google Scholar
• MADSEN KL, DOYLE JS, TAVERNINI MM et al.: Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology (2000) 118:1094–1105.
   PubMed Web of Science ®Google Scholar
• DAVIDSON NJ, LEACH MW, FORT MM et al.: T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. Exp. Med. (1996) 184:241–251.
   PubMed Web of Science ®Google Scholar
• DAVIDSON NJ, HUDAK SA, LESLEY RE et al.: IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. Innnunol. (1998) 161:3143–3149.
   Google Scholar
• MOSER M, MURPHY KM: Dendritic cellregulation of TH1-TH2 development. Nat. Inonunol. (2000) 1:199–205.
   PubMed Web of Science ®Google Scholar
• BERG DJ, DAVIDSON N, KUHN R et al.: Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. I Clin. Invest. (1996) 98:1010–1020.
   PubMed Web of Science ®Google Scholar
• BERTRAND V, QUERE S, GUIMBAUD R et al.: Effects of murine recombinant interleukin-10 on the inflammatory disease of rats transgenic for HLA-B27 and human beta 2-microglobulin. Eur. Cytokine Netw. (1998) 9:161–170.
   PubMed Web of Science ®Google Scholar
• DUCHMANN R, SCHMITT E, KNOLLE P, MEYER ZUM BUSCHENFELDE KH, NEURATH M: Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur. I Inonunol. (1996) 26:934–938.
   Google Scholar
• GROOL TA, VAN DULLEMEN H, MEENAN J et al.: Anti-inflammatory effect of interleukin-10 in rabbit immune complex-induced colitis. Scand. Gastroenterol. (1998) 33:754–758.
   PubMed Web of Science ®Google Scholar
• HERFARTH HH, MOHANTY SP, RATH HC, TONKONOGY S, SARTOR RB: Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut (1996) 39:836–845.
   PubMed Web of Science ®Google Scholar
• RIBBONS KA, THOMPSON JH, LIU X et al.: Anti-inflammatory properties of interleukin-10 administration in hapten-induced colitis. Eur. Pharinacol. (1997) 323:245–254.
   PubMed Web of Science ®Google Scholar
• TOMOYOSE M, MITSUYAMA K, ISHIDA H, TOYONAGA A, TANIKAWA K: Role of interleukin-10 in a murine model of dextran sulfate sodium-induced colitis. Scand. Gastroenterol. (1998) 33:435–440.
   PubMed Web of Science ®Google Scholar
• POWRIE F, CORREA-OLIVEIRA R, MAUZE S, COFFMAN RL: Regulatory interactions between CD45RBhigh and CD45RB1ow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. I Exp. Med. (1994) 179:589–600.
   PubMed Web of Science ®Google Scholar
• ASSEMAN C, MAUZE S, LEACH MW, COFFMAN RL, POWRIE F: An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. I Exp. Med. (1999) 190:995–1004.
   PubMed Web of Science ®Google Scholar
• •Underlines the importance of IL-10 in controlling mucosal tolerance.
   Google Scholar
• POUSSIER P, NING T, BANERJEE D, JULIUS M: A unique subset of self-specific intraintestinal T cells maintains gut integrity. I Exp. Med. (2002) 195:1491–1497.
   PubMed Web of Science ®Google Scholar
• ASSEMAN C, POWRIE F: Interleukin 10 is a growth factor for a population of regulatory T cells. Gut (1998) 42:157–158.
   PubMed Web of Science ®Google Scholar
• GROUX H, O& GARRA A, BIGLER M et al.: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature (1997) 389:737–742.
   Google Scholar
• DE WINTER H, ELEWAUT D, TUROVSKAYA 0 et al.: Regulation of mucosal immune responses by recombinant interleukin 10 produced by intestinal epithelial cells in mice. Gastroenterology (2002) 122:1829–1841.
   Google Scholar
• HAGENBAUGH A, SHARMA S, DUBINETT SM et al: Altered immune responses in interleukin 10 transgenic mice. Exp. Med. (1997) 185:2101–2110.
   PubMed Web of Science ®Google Scholar
• •Describes the possibility of IL-10-producing T cells as a treatment for experimental colitis.
   Google Scholar
• AITHAL GP, CRAGGS A, DAY CP et al.: Role of polymorphisms in the interleukin-10 gene in determining disease susceptibility and phenotype in inflammatory bowel disease. Dig. Dis. Sci. (2001) 46:1520–1525.
   PubMed Web of Science ®Google Scholar
• KLEIN W, TROMM A, GRIGA T et al.: The IL-10 gene is not involved in the predisposition to inflammatory bowel disease. Electrophoresis (2000) 21:3578–3582.
   PubMed Web of Science ®Google Scholar
• PARKES M, SATSANGI J, JEWELL D: Contribution of the IL-2 and IL-10 genes to inflammatory bowel disease (IBD) susceptibility. Clin. Exp. Immunol. (1998) 113:28–32.
   PubMed Web of Science ®Google Scholar
• BRISTOL IJ, FARMER MA, CONG Y et al.: Heritable susceptibility for colitis in mice induced by IL-10 deficiency. Inflamm. Bowel Dis. (2000) 6:290–302.
   PubMed Web of Science ®Google Scholar
• MAHLER M, MOST C, SCHMIDTKE S et al.: Genetics of colitis susceptibility in IL-10-deficient mice: backcross versus F2 results contrasted by principal component analysis. Genomics (2002) 80:274–282.
   PubMed Web of Science ®Google Scholar
• FARMER MA, SUNDBERG JP, BRISTOL IJ et al: A major quantitative trait locus on chromosome 3 controls colitis severity in IL-10-deficient mice. Proc. Nati Acad. Sci. USA (2001) 98:13820–13825.
   PubMed Web of Science ®Google Scholar
• AUTSCHBACH F, BRAUNSTEIN J, HELMKE B et al.: M situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am. Pathol (1998) 153:121–130.
   PubMed Web of Science ®Google Scholar
• GASCHE C, BAKOS S, DEJACO C et al: IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease. I Clin. Immunol. (2000) 20:362–370.
   Web of Science ®Google Scholar
• NIESSNER M, VOLK BA: Altered Thl/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin. Exp. Immunol. (1995) 101:428–435.
   PubMed Web of Science ®Google Scholar
• SEWNATH ME, OLSZYNA DP, BIRJMOHUN R et al: IL-10-deficient mice demonstrate multiple organ failure and increased mortality during Escherichia coliperitonitis despite an accelerated bacterial clearance. J. Immunol (2001) 166:6323–6331.
   PubMed Web of Science ®Google Scholar
• PAJKRT D, CAMOGLIO L, TIEL-VAN BUUL MC et al.: Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration. Immunol (1997) 158:3971–3977.
   Google Scholar
• PAJKRT D, VAN DER POLL T, LEVI M et al.: Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood (1997) 89:2701–2705.
   Google Scholar
• ISHIZUKA K, SUGIMURA K, HOMMA T et al.: Influence of interleukin-10 on the interleukin-1 receptor antagonist/ interleukin-1 beta ratio in the colonic mucosa of ulcerative colitis. Digestion (2001) 63:22–27.
   PubMed Web of Science ®Google Scholar
• SCHREIBER S, HEINIG T, THIELE HG,RAEDLER A: Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology (1995) 108:1434–1444.
   PubMed Web of Science ®Google Scholar
• ROSENBLUM TY, JOHNSON RC, SCHMAHAI TJ: Preclinical safety evaluation of recombinant human interleukin-10. Regal. Toxicol Pharmacol (2002) 35:56–71.
   PubMed Web of Science ®Google Scholar
• COLOMBEL JF, RUTGEERTS P, MALCHOW H et al.: Interleuldn 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut (2001) 49:42–46.
   PubMed Web of Science ®Google Scholar
• LAUW FN, PAJKRT D, HACK CE et al:Proinflammatory effects of IL-10 during human endotoxemia. 1 Immunol. (2000) 165:2783–2789.
   PubMed Web of Science ®Google Scholar
• TILG H, VAN MONTFRANS C, VAN DEN ENDE A et al.: Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut (2002) 50:191–195.
   Google Scholar
• •Stretches the disadvantages of systemic IL-10 treatment.
   Google Scholar
• VAN MONTFRANS C, HOOTJBERG E, RODRIGUEZ PENA MS et al: Generation of regulatory gut-homing human T lymphocytes using ex vivo interleukin 10 gene transfer. Gastroenterology (2002) 123: 1877-1888.
   Google Scholar
• ••Describes the possibility to generate IL-10-producing human T cells by gene therapy.
   Google Scholar
• LINDSAY JO, CIESIELSKI CJ, SCHEININ T, BRENNAN FM, HODGSON HJ: Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut (2003) 52:363–369.
   PubMed Web of Science ®Google Scholar
• MOWAT AM: Anatomical basis of tolerance and immunity to intestinal antigens. Nat. Rev. Immunol (2003) 3:331–341.
   PubMed Web of Science ®Google Scholar
• MARSHALL E: Gene therapy a suspect in leukemia-like disease. Science (2002) 29:34–35.
   Google Scholar
• CHECK E: Regulators split on gene therapy as patient shows signs of cancer. Nature (2002) 419:545–546.
   PubMed Web of Science ®Google Scholar